CENTOGENE News & Events Header Image Broschure

News

Stay up to date and read about our most recent milestones towards achieving CENTOGENE’s mission: To enable the cure of 100 rare diseases in 10 years.

Interested in receiving the latest news around the clock? Follow us on LinkedIn.

CENTOGENE Marks Rare Disease Day 2020 With a Global Line up of Events

Cambridge, MA, USA & Rostock/Berlin, Germany, February 29, 2020 – CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that…

Read more

Rare Disease Associations Fight for Better Patient Health Care

On Saturday, February 29th, CENTOGENE, OMER, and ALIBER will celebrate International Rare Disease Day with an event for patients, healthcare…

Read more

CENTOGENE Expands Senior Leadership Team with Newly Appointed Chief Data Officer

Cambridge, MA, USA & Rostock, Germany – February 25, 2020 – CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that…

Read more

CENTOGENE Biobank Receives Accreditation from College of American Pathologists

State-of-the-art Biorepository in Rostock, Germany is the first CAP-accredited repository outside the U.S.

Cambridge, MA, USA & Rostock, Germany…

Read more

CentoMD® Update Reveals Continued Growth of Rare Hereditary Disease Knowledge Base

Supporting Patients for Accelerated Diagnosis and Treatment Development

Cambridge, MA USA & Rostock, Germany December 13, 2019 - In an update…

Read more

CENTOGENE Expands Executive Leadership Team

Cambridge, MA USA & Rostock, Germany December 6, 2019 – CENTOGENE (Nasdaq: CNTG) today announced the expansion of its executive leadership team with…

Read more

CENTOGENE gibt vorübergehende Auszeit von Holger Friedrich von Position als Aufsichtsrat bekannt

ROSTOCK/BERLIN, Deutschland und CAMBRIDGE, MA, USA 21. November 2019 (GLOBE NEWSWIRE) - CENTOGENE (Nasdaq: CNTG), ein auf seltene Erkrankungen…

Read more

CENTOGENE Announces Temporary Leave of Absence of Holger Friedrich from the Supervisory Board

CAMBRIDGE, Mass. and ROSTOCK and BERLIN, Germany, November 21, 2019 (GLOBE NEWSWIRE) – CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on…

Read more

CENTOGENE Signs New Collaboration with PTC Therapeutics for Global Diagnostic Testing Program

Focus on Aromatic L-amino Acid Decarboxylase (AADC) Deficiency

Read more

CENTOGENE Signs Data Access and Collaboration Agreement with Pfizer Inc.

Accelerating new rare disease therapies through collaboration agreement

Read more

For Further Inquiries Please Contact

Press Contact

Melissa Hall

Corporate Communications

Email Us

Downloads

Here you can find forms, brochures, flyer and information sheets for download (PDF) about the broad genetic testing product and service portfolio of CENTOGENE.

Downloads